Pharmaceutical Post Publication on our Sol-Gel innovation

A novel ocular in situ gelling delivery system optimizes the induction of diagnostic and preoperative mydriasis

“Mydriasis is required prior to many eye examinations and ophthalmic surgeries. Several pharmaceutic dosage forms using mainly phenylephrine hydrochloride ( and tropicamide ( as active ingredients have been described, however, no optimal drug delivery strategy has reached the market. We hypothesized that an ophthalmic in situ gelling system for the delivery of PHE and TPC could induce a fast, long lasting and efficient mydriasis following the topical administration of a single drop”

L’attribut alt de cette image est vide, son nom de fichier est Innovation-pharma-post-1-700x501.png.
L’attribut alt de cette image est vide, son nom de fichier est Innovation-pharma-post-2-700x496.png.
L’attribut alt de cette image est vide, son nom de fichier est Innovation-pharma-post-3-700x498.png.